# US 2026/0055392 A1 · Method for preparing linear closed dna and plasmid for use in the method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0055392 A1
- Document ID: US20260055392A1
- Status: Published application
- Kind: A1
- Application number: 19/102,713
- Filed: 2023-08-10
- Published: 2026-02-26
- Earliest claimed: 2022-08-10
- Assignees: Zhenjiang Probio Biotech Co., Ltd.
- Applicants: Zhenjiang Probio Biotech Co., Ltd.
- Inventors: Xinmiao ZHANG; Junpeng CHEN
- Web page: https://patentgrep.com/patent/US20260055392A1

## CPC

- C12N 15/101: {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/1017: {by filtration, e.g. using filters, frits, membranes}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N 15/85: for animal cells
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 301/11: Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
- C12Y 301/11002: Exodeoxyribonuclease III (3.1.11.2)
- C12Y 301/11003: Exodeoxyribonuclease (lambda-induced) (3.1.11.3)
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 2800/10: Plasmid DNA
- C12N 2800/107: for mammalian
- C12N 2800/70: Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are a method for preparing a linear closed DNA and a plasmid for use in the method. The plasmid comprises two editable regions of prokaryotic telomerase target sequences which are connected in tandem in the same direction, and both ends of the editing regions are independently provided with one or more restriction endonuclease digestion sites. The method can yield high-purity LcDNA and can be better applied to clinical research and commercial applications.

## Claims

### Claim 1

A plasmid comprising two prokaryotic telomerase target sequences that each have an editable region,
the editable regions of the two prokaryotic telomerase target sequences being connected in tandem in the same direction, and
each end of each editing region being independently provided with one or more restriction endonuclease digestion sites.

### Claim 2 (depends on 1)

The plasmid of claim 1, wherein the plasmid has a length of ≤2500 bp.

### Claim 3 (depends on 1)

The plasmid of claim 1, further comprising a prokaryotic replicon and a selectable gene.

### Claim 4 (depends on 3)

The plasmid of claim 3, wherein each restriction endonuclease digestion site at each end of each editing region is selected from the group consisting of digestion sites of AccI, AflII, AgeI, ApaI, AscI, AvrII, BamHI, BglI, BglII, BsaI, BspQI, BstBI, BsteII, ClaI, EcoNI, EcoRI, EcoRV, FseI, HindIII, KpnI, MfeI, MluI, NcoI, NdeI, NheI, NotI, PacI, PstI, PvuI, PvuII, SacI, SacII, SalI, ScaI, SmaI, SpeI, StuI, SwaI, XbaI, XhoI, XmaI, and any combination thereof.

### Claim 5 (depends on 4)

The plasmid of claim 4, wherein each restriction endonuclease digestion site at one end of each editing region is selected from the group consisting of HindIII, SalI, SmaI, and BamHI, and each restriction endonuclease digestion site at the other end of each editing region is selected from the group consisting of EcoRV, XbaI, KpnI, and EcoRI.

### Claim 6 (depends on 1)

The plasmid of claim 1, wherein each prokaryotic telomerase target sequence comprises a sequence set forth in SEQ ID NO: 1 or a nucleotide sequence that has at least 80% identity with the sequence set forth in SEQ ID NO: 1 and is capable of functioning as a telomerase.

### Claim 7 (depends on 1)

The plasmid of claim 1, further comprising a nucleotide sequence that has at least 80% identity with the sequence set forth in SEQ ID NO: 2.

### Claim 8

A recombinant plasmid comprising:
two prokaryotic telomerase target sequences that each have an editable region, the editable regions of the two prokaryotic telomerase target sequences being connected in tandem in the same direction, and
each end of each editing region being independently provided with one or more restriction endonuclease digestion sites; and
a gene of interest inserted between the two prokaryotic telomerase target sequences.

### Claim 9

A method for preparing a linear closed DNA, the method comprising:
digesting a recombinant plasmid comprising a gene of interest with a prokaryotic telomerase to separate the gene of interest from a heterogeneous nucleic acid in the recombinant plasmid;
using at least two restriction endonucleases for digestion such that the ends of the heterogeneous nucleic acid are exposed;
removing the heterogeneous nucleic acid by using an exonuclease; and
separating and purifying the linear closed DNA containing the gene of interest,
wherein the recombinant plasmid comprises two prokaryotic telomerase target sequences and restriction endonuclease digestion sites, and the gene of interest is between the two prokaryotic telomerase target sequences.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The method of claim 9, wherein the exonuclease includes Exonuclease III and/or T5 Exonuclease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the exonuclease is used in an amount of from 3000-6000 U/mg.

### Claim 13 (depends on 12)

The method of claim 12, wherein the digestion temperature of the exonuclease is from 34-40° C., and the digestion time of the exonuclease is from 2-12 hours.

### Claim 14 (depends on 9)

The method of claim 9, further comprising, after removing the heterogeneous nucleic acid by using the exonuclease, adding EDTA to a final concentration of from 1-50 mM and raising the temperature to from 70-80° C. for from 5-30 minutes.

### Claim 15 (depends on 9)

The method of claim 9, wherein, after finishing the digestion of the recombinant plasmid comprising a gene of interest with the prokaryotic telomerase, and/or after finishing the exposure of the ends of the heterogeneous nucleic acid using the at least two restriction endonucleases, the temperature is raised to from 70-80° C. for from 5-30 minutes.

### Claim 16 (depends on 9)

The method of claim 9, wherein the separating and purifying the linear closed DNA containing the gene of interest comprises at least one of gel filtration chromatography, anion exchange chromatography, concentration and liquid exchange, or sterilization filtration.

### Claim 17 (depends on 16)

The method of claim 16, wherein the separating and purifying the linear closed DNA containing the gene of interest comprises gel filtration chromatography and anion exchange chromatography.

### Claim 18 (depends on 17)

The method of claim 17, wherein a packing for the gel filtration chromatography is Bestarose 6FF, and an eluate from the first ultraviolet peak with an absorbance of ≥50 mAu is collected.

### Claim 19 (depends on 18)

The method of claim 18, wherein a packing for the anion exchange chromatography is Fractogel EMD DEAE.

### Claim at position 20

20-21. (canceled)

### Claim 22 (depends on 1)

A kit comprising a prokaryotic telomerase and the plasmid of claim 1.

### Claim 23

(canceled)

### Claim 24 (depends on 9)

A linear closed DNA prepared by the method of claim 9.

### Claim 25 (depends on 8)

A kit comprising a prokaryotic telomerase and the recombinant plasmid of claim 8.
